OR WAIT null SECS
© 2022 MJH Life Sciences™ and Formulary Watch. All rights reserved.
Telbivudine was approved on October 25, 2006, for the treatment of chronic hepatitis B virus (HBV) in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.